---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-000780"
form_type: "8-K"
ticker: "IMCR"
cik: "0001671927"
company_name: "Immunocore Holdings plc"
filed_at: "2026-01-09T23:59:59+00:00"
generated_at: "2026-05-16T11:04:25.444870+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Immunocore reports prelim cash $864M, sets 2026 priorities including TEBE-AM enrollment completion in 1H 2026

## Summary
- Preliminary unaudited cash, cash equivalents and marketable securities ~$864M as of Dec 31, 2025.
- TEBE-AM Phase 3 cutaneous melanoma trial enrollment completion expected 1H 2026; topline data as early as 2H 2026.
- Phase 1/2 PRAME data expected 2H 2026: brenetafusp combos in ovarian and NSCLC, initial IMC-P115C data.
- First patient in Phase 1 type 1 diabetes trial (IMC-S118AI) expected 1H 2026; autoimmune trial app for atopic dermatitis in 2H 2026.
- KIMMTRAK enters 5th year post-approval; expects moderate revenue growth driven by community and global penetration.

## SEC filing metadata
- accession: 0001140361-26-000780
- form_type: 8-K
- ticker: IMCR
- cik: 0001671927
- company_name: Immunocore Holdings plc
- filed_at: 2026-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671927/000114036126000780/0001140361-26-000780-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671927/000114036126000780/ef20062561_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-000780
- JSON: https://secwatch.observer/filing/0001140361-26-000780.json
- Plain text: https://secwatch.observer/filing/0001140361-26-000780.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.